Breakthrough in Tumor Treatment with Cryoablation Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Source: PRnewswire
- Clinical Data Highlights: The ICESECRET trial demonstrated an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% remaining recurrence-free at a median follow-up of 4 years, indicating the efficacy and safety of cryoablation technology for small tumors.
- Independent Study Results: An independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes, further validating the application potential of ProSense® in early-stage breast cancer treatment.
- Technology Promotion and Training: The ECIO 2026 conference featured the first dedicated breast cryoablation course, attracting significant participation from physicians, highlighting the growing clinical recognition and interest in ProSense® for treating breast cancer, fibroadenomas, and kidney cancer.
- FDA Approval Driving Market: Following FDA clearance, global adoption and clinical interest in ProSense® are on the rise, marking cryoablation's potential as a minimally invasive alternative to surgery and its possible establishment as a standard treatment option.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.139
Low
3.00
Averages
3.00
High
3.00
Current: 0.139
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's $1 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to compliance and proactive capital market strategies.
- Impact on Shares: Following the reverse split, the number of issued ordinary shares will decrease from 84,201,034 to approximately 2,806,701, ensuring that shareholders' percentage ownership remains unchanged, although minor adjustments will be made for fractional shares.
- Market Confidence Strategy: By implementing this reverse split, IceCure aims to enhance its stock price before the compliance deadline of November 9, 2026, thereby boosting investor confidence and supporting its broader capital market strategy.
See More
IceCure Medical Announces 1-for-30 Reverse Stock Split
- Reverse Stock Split: IceCure Medical announced a 1-for-30 reverse stock split effective June 4, 2026, aimed at raising its share price above Nasdaq's minimum bid requirement of $1, thereby helping the company maintain its Nasdaq listing.
- Share Count Reduction: Following the reverse split, the outstanding share count will decrease from 84.2 million to approximately 2.8 million shares, while shareholders' ownership stakes will largely remain unchanged, impacting stock options, warrants, and equity awards.
- Compliance Deadline: The company has until November 9, 2026, to regain compliance, with the reverse split being a response to the current stock price of $0.16, which is down 19%, indicating the market pressures the company is facing.
- Market Reaction: IceCure Medical's stock is currently trading at $0.16, and the decision for a reverse split may affect investor confidence, although the company hopes to improve its stock performance and attract more investment through this measure.
See More
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq's $1.00 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to regulatory compliance and proactive management of its capital markets strategy.
- Impact on Shares: The reverse split will reduce the number of issued ordinary shares from 84,201,034 to approximately 2,806,701, ensuring that all shareholders' ownership percentages remain unchanged, although minor adjustments will be made for fractional shares to maintain fairness.
- Market Reaction Anticipation: The reverse split is set to take effect on June 4, 2026, with shares trading at the adjusted price on Nasdaq, aiming to boost investor confidence and attract further investment by enhancing the stock price.
See More
Breakthrough in Tumor Treatment with Cryoablation Technology
- Clinical Data Highlights: The ICESECRET trial demonstrated an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% remaining recurrence-free at a median follow-up of 4 years, indicating the efficacy and safety of cryoablation technology for small tumors.
- Independent Study Results: An independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes, further validating the application potential of ProSense® in early-stage breast cancer treatment.
- Technology Promotion and Training: The ECIO 2026 conference featured the first dedicated breast cryoablation course, attracting significant participation from physicians, highlighting the growing clinical recognition and interest in ProSense® for treating breast cancer, fibroadenomas, and kidney cancer.
- FDA Approval Driving Market: Following FDA clearance, global adoption and clinical interest in ProSense® are on the rise, marking cryoablation's potential as a minimally invasive alternative to surgery and its possible establishment as a standard treatment option.
See More
IceCure Medical Receives 180-Day Nasdaq Compliance Extension
- Compliance Extension: IceCure Medical has received a 180-day extension from Nasdaq until November 9, 2026, to meet the minimum bid price requirement of $1.00 per share for at least 10 consecutive business days, indicating the company meets all other listing criteria.
- Reverse Split Consideration: The company may consider a reverse share split if necessary to regain compliance, reflecting management's commitment to restoring the stock price and maintaining market presence.
- Initial Notification Context: IceCure first received notice from Nasdaq on November 12, 2025, for failing to meet the minimum bid price for 30 consecutive days, with the initial compliance period expiring on May 11, 2026, highlighting the compliance challenges faced by the company.
- Trading Continuity: Despite compliance issues, IceCure's shares will continue to trade on the Nasdaq Capital Market under the ticker “ICCM,” indicating the company's ongoing presence in the market.
See More
IceCure Granted Extended Compliance Period by Nasdaq
- Compliance Extension: IceCure Medical has been granted an additional 180-day compliance period by Nasdaq until November 9, 2026, to meet the minimum $1.00 bid price requirement, demonstrating the company's commitment to maintaining its listing status.
- Price Requirement Not Met: Despite failing to maintain the minimum bid price over the previous 30 trading days, Nasdaq acknowledged the company's market value and compliance with other listing requirements, indicating potential for future compliance.
- Reverse Split Consideration: IceCure has indicated that it may consider a reverse share split if necessary to meet the price requirement, a strategy that could impact shareholder structure and market confidence.
- Ongoing Trading Status: The current notification has no immediate effect on the trading of the company's ordinary shares, which will continue to trade under the symbol “ICCM,” ensuring ongoing investor interest and confidence in the company's future.
See More
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's $1 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to compliance and proactive capital market strategies.
- Impact on Shares: Following the reverse split, the number of issued ordinary shares will decrease from 84,201,034 to approximately 2,806,701, ensuring that shareholders' percentage ownership remains unchanged, although minor adjustments will be made for fractional shares.
- Market Confidence Strategy: By implementing this reverse split, IceCure aims to enhance its stock price before the compliance deadline of November 9, 2026, thereby boosting investor confidence and supporting its broader capital market strategy.
See More
IceCure Medical Announces 1-for-30 Reverse Stock Split
- Reverse Stock Split: IceCure Medical announced a 1-for-30 reverse stock split effective June 4, 2026, aimed at raising its share price above Nasdaq's minimum bid requirement of $1, thereby helping the company maintain its Nasdaq listing.
- Share Count Reduction: Following the reverse split, the outstanding share count will decrease from 84.2 million to approximately 2.8 million shares, while shareholders' ownership stakes will largely remain unchanged, impacting stock options, warrants, and equity awards.
- Compliance Deadline: The company has until November 9, 2026, to regain compliance, with the reverse split being a response to the current stock price of $0.16, which is down 19%, indicating the market pressures the company is facing.
- Market Reaction: IceCure Medical's stock is currently trading at $0.16, and the decision for a reverse split may affect investor confidence, although the company hopes to improve its stock performance and attract more investment through this measure.
See More
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq's $1.00 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to regulatory compliance and proactive management of its capital markets strategy.
- Impact on Shares: The reverse split will reduce the number of issued ordinary shares from 84,201,034 to approximately 2,806,701, ensuring that all shareholders' ownership percentages remain unchanged, although minor adjustments will be made for fractional shares to maintain fairness.
- Market Reaction Anticipation: The reverse split is set to take effect on June 4, 2026, with shares trading at the adjusted price on Nasdaq, aiming to boost investor confidence and attract further investment by enhancing the stock price.
See More
Breakthrough in Tumor Treatment with Cryoablation Technology
- Clinical Data Highlights: The ICESECRET trial demonstrated an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% remaining recurrence-free at a median follow-up of 4 years, indicating the efficacy and safety of cryoablation technology for small tumors.
- Independent Study Results: An independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes, further validating the application potential of ProSense® in early-stage breast cancer treatment.
- Technology Promotion and Training: The ECIO 2026 conference featured the first dedicated breast cryoablation course, attracting significant participation from physicians, highlighting the growing clinical recognition and interest in ProSense® for treating breast cancer, fibroadenomas, and kidney cancer.
- FDA Approval Driving Market: Following FDA clearance, global adoption and clinical interest in ProSense® are on the rise, marking cryoablation's potential as a minimally invasive alternative to surgery and its possible establishment as a standard treatment option.
See More
IceCure Medical Receives 180-Day Nasdaq Compliance Extension
- Compliance Extension: IceCure Medical has received a 180-day extension from Nasdaq until November 9, 2026, to meet the minimum bid price requirement of $1.00 per share for at least 10 consecutive business days, indicating the company meets all other listing criteria.
- Reverse Split Consideration: The company may consider a reverse share split if necessary to regain compliance, reflecting management's commitment to restoring the stock price and maintaining market presence.
- Initial Notification Context: IceCure first received notice from Nasdaq on November 12, 2025, for failing to meet the minimum bid price for 30 consecutive days, with the initial compliance period expiring on May 11, 2026, highlighting the compliance challenges faced by the company.
- Trading Continuity: Despite compliance issues, IceCure's shares will continue to trade on the Nasdaq Capital Market under the ticker “ICCM,” indicating the company's ongoing presence in the market.
See More
IceCure Granted Extended Compliance Period by Nasdaq
- Compliance Extension: IceCure Medical has been granted an additional 180-day compliance period by Nasdaq until November 9, 2026, to meet the minimum $1.00 bid price requirement, demonstrating the company's commitment to maintaining its listing status.
- Price Requirement Not Met: Despite failing to maintain the minimum bid price over the previous 30 trading days, Nasdaq acknowledged the company's market value and compliance with other listing requirements, indicating potential for future compliance.
- Reverse Split Consideration: IceCure has indicated that it may consider a reverse share split if necessary to meet the price requirement, a strategy that could impact shareholder structure and market confidence.
- Ongoing Trading Status: The current notification has no immediate effect on the trading of the company's ordinary shares, which will continue to trade under the symbol “ICCM,” ensuring ongoing investor interest and confidence in the company's future.
See More
